DE69315440T2 - Eine Methode zur Herstellung von Hepatozytwachstumsfaktor und eine Zelllinie - Google Patents

Eine Methode zur Herstellung von Hepatozytwachstumsfaktor und eine Zelllinie

Info

Publication number
DE69315440T2
DE69315440T2 DE69315440T DE69315440T DE69315440T2 DE 69315440 T2 DE69315440 T2 DE 69315440T2 DE 69315440 T DE69315440 T DE 69315440T DE 69315440 T DE69315440 T DE 69315440T DE 69315440 T2 DE69315440 T2 DE 69315440T2
Authority
DE
Germany
Prior art keywords
met
hgf
antibody
substance
cell line
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69315440T
Other languages
English (en)
Other versions
DE69315440D1 (de
Inventor
Donna L Faletto
Ilan Tsarfaty
Sing Rong
Marianne Oskarsson
Woude George F Vande
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
US Department of Army
Original Assignee
US Department of Health and Human Services
US Department of Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, US Department of Army filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69315440D1 publication Critical patent/DE69315440D1/de
Publication of DE69315440T2 publication Critical patent/DE69315440T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69315440T 1992-09-18 1993-09-15 Eine Methode zur Herstellung von Hepatozytwachstumsfaktor und eine Zelllinie Expired - Fee Related DE69315440T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94606192A 1992-09-18 1992-09-18
PCT/US1993/008531 WO1994006909A2 (en) 1992-09-18 1993-09-15 A method of preventing tumor metastasis

Publications (2)

Publication Number Publication Date
DE69315440D1 DE69315440D1 (de) 1998-01-08
DE69315440T2 true DE69315440T2 (de) 1998-07-09

Family

ID=25483898

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69315440T Expired - Fee Related DE69315440T2 (de) 1992-09-18 1993-09-15 Eine Methode zur Herstellung von Hepatozytwachstumsfaktor und eine Zelllinie
DE69334159T Expired - Lifetime DE69334159D1 (de) 1992-09-18 1993-09-15 Medizinische Verwendung eines Antikörpers oder eines Antikörperfragments gegen die extrazelluläre Domäne von Met zur Prevention von Metastasen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69334159T Expired - Lifetime DE69334159D1 (de) 1992-09-18 1993-09-15 Medizinische Verwendung eines Antikörpers oder eines Antikörperfragments gegen die extrazelluläre Domäne von Met zur Prevention von Metastasen

Country Status (10)

Country Link
EP (2) EP0805203B1 (de)
JP (2) JP3553936B2 (de)
AT (2) ATE368738T1 (de)
AU (1) AU675968B2 (de)
CA (1) CA2144856A1 (de)
DE (2) DE69315440T2 (de)
DK (1) DK0662130T3 (de)
ES (1) ES2112997T3 (de)
GR (1) GR3026165T3 (de)
WO (1) WO1994006909A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US6566098B1 (en) 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
DE69310525T2 (de) * 1992-09-16 1997-10-02 Genentech Inc Schutz gegen leberschäden mit hgf
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US6855685B2 (en) 1995-10-24 2005-02-15 Toshikazu Nakamura Anti-cancer agent
JP3832674B2 (ja) * 1995-10-24 2006-10-11 敏一 中村 抗癌剤
WO1998019696A1 (en) * 1996-11-05 1998-05-14 Smithkline Beecham Corporation Hepatocyte growth factor antagonists
WO2000025727A2 (en) * 1998-11-04 2000-05-11 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of flumethasone, fluocinolone acetonide fluoromethasone for manufacture of a medicament for the treatment of tumours
IL131142A0 (en) * 1999-07-28 2001-01-28 Rad Ramot Prognosis of breast cancer and other diseases
US7459536B1 (en) 1999-11-09 2008-12-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HGF-SF monoclonal antibody combinations
CA2452445C (en) * 2000-06-29 2011-02-15 North Shore-Long Island Jewish Health System Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
MXPA05008521A (es) * 2003-02-13 2005-10-20 Pharmacia Corp Anticuerpos a c-met para el tratamiento de canceres.
TW201319088A (zh) 2003-07-18 2013-05-16 Amgen Inc 對肝細胞生長因子具專一性之結合劑
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
PT1773885E (pt) 2004-08-05 2010-07-21 Genentech Inc Antagonistas anti-cmet humanizados
ES2440953T3 (es) 2005-03-31 2014-01-31 The General Hospital Corporation Modulación de la actividad de HGF/HGFR para tratar un linfedema
KR101259655B1 (ko) 2005-04-15 2013-04-30 제넨테크, 인크. Ｈｇｆ 베타 사슬 변이체
WO2007119447A1 (ja) 2006-03-20 2007-10-25 Seikagaku Corporation 関節リウマチの処置剤
EP2004693B1 (de) 2006-03-30 2012-06-06 Novartis AG Zusammensetzungen und verfahren zur verwendung von c-met-antikörpern
EP3511342B1 (de) 2010-03-10 2024-01-17 Genmab A/S Monoklonale antikörper gegen c-met
US8637027B2 (en) 2010-11-03 2014-01-28 Argen-X B.V. Anti c-Met antibodies
US9150613B2 (en) 2011-04-02 2015-10-06 Washington State University Hepatocyte growth factor mimics as therapeutic agents
CN107090038A (zh) 2011-06-30 2017-08-25 霍夫曼-拉罗奇有限公司 抗c‑met抗体配制剂
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
BR112016021383A2 (pt) 2014-03-24 2017-10-03 Genentech Inc Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
WO2016042412A1 (en) 2014-09-16 2016-03-24 Symphogen A/S Anti-met antibodies and compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362716A (en) * 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
US5648273A (en) * 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
GB9003621D0 (en) * 1990-02-16 1990-04-11 Imp Cancer Res Tech Protein factor
JP2784455B2 (ja) * 1990-05-09 1998-08-06 敏一 中村 肝硬変治療剤
DE69133349T2 (de) * 1990-09-14 2004-10-07 Us Health Ein nicht-mitogener kompetitiver hgf-antagonist
JPH07508420A (ja) * 1992-05-18 1995-09-21 ジェネンテク，インコーポレイテッド 肝細胞成長因子変異体

Also Published As

Publication number Publication date
CA2144856A1 (en) 1994-03-31
DK0662130T3 (da) 1998-08-10
GR3026165T3 (en) 1998-05-29
EP0662130A1 (de) 1995-07-12
ATE368738T1 (de) 2007-08-15
DE69334159D1 (de) 2007-09-13
JPH08504093A (ja) 1996-05-07
AU675968B2 (en) 1997-02-27
WO1994006909A3 (en) 1994-05-26
EP0805203A1 (de) 1997-11-05
ES2112997T3 (es) 1998-04-16
DE69315440D1 (de) 1998-01-08
JP2004002440A (ja) 2004-01-08
JP3553936B2 (ja) 2004-08-11
AU4855593A (en) 1994-04-12
WO1994006909A2 (en) 1994-03-31
ATE160585T1 (de) 1997-12-15
EP0662130B1 (de) 1997-11-26
EP0805203B1 (de) 2007-08-01

Similar Documents

Publication Publication Date Title
DE69315440T2 (de) Eine Methode zur Herstellung von Hepatozytwachstumsfaktor und eine Zelllinie
ATE236271T1 (de) Verwendung der ndv zur herstellung eines medikaments zur krebsbehandlung
ATE378403T1 (de) Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
ATE347910T1 (de) Zusammensetzungen zur behandlung von ischamischem gewebe
DE69435330D1 (de) Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
DE3486160T2 (de) Modifizierte lebende Pseudo-Rabies-Viren, diese enthaltende Impfstoffe gegen Pseudo-Rabies, Verfahren zur Herstellung und Verfahren zur Verwendung derselben.
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
DE69718150D1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
DE69211899D1 (de) Siloxan modifizierter Polyester zur Behandlung von Fasern
DE69502554D1 (de) Verfahren zur Herstellung von Bisphenol-A und Polysiloxan-Katalysator dafür
DE69306915D1 (de) Kombination zur Detektion von Weichgewebeanomalien
KR950700079A (ko) 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease)
DE69314234T2 (de) Konservierte Polysiloxanemulsion zur Behandlung von Geweben
DE69405919T2 (de) Zusammensetzungen zur Behandlung von Keratinfasern
FI982745A (fi) TIE-2-reseptoriligandit (TIE-ligandi-3; TIE-ligandi-4) ja niiden käytt"
DE69328091T2 (de) Bindungspeptide zur interaktion mit wachstumsfaktoren als liganden des rezeptors des epidermiswachstumsfactor und des erbb-2-rezeptor
ATE349225T1 (de) Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv
DE69127344D1 (de) Katalysierte Äquilibrierung von Polyorganosiloxanen und Verfahren zur Herstellung von Cyclosiloxanen
DE69301904T2 (de) Zusammensetzung zur behandlung von keratinfasern
ATE504309T1 (de) Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis
DE69304418T2 (de) Verfahren zur Herstellung von 4,4'-Biphenol
DE69408394D1 (de) 4-Piperidino-piperidin zur Behandlung von Tumoren
ATE222927T1 (de) Monoklonaler antikörper gegen den tumorzytotoxischen faktor ii (tcf-ii)
DE60020729D1 (de) Verfahren und zusammensetzung zur behandlung von adenovirale augeninfektionen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee